Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
NanoViricides, Inc. is a clinical-stage biotechnology company focused on the discovery and development of broad-spectrum antiviral therapies. The company operates within the biopharmaceutical and antiviral drug development industry, with a core emphasis on treating viral infections for which effective therapies are limited or absent. NanoViricides does not currently have any FDA-approved products and has not generated product revenue, positioning it as a development-stage enterprise.
The company’s primary value proposition is its proprietary nanoviricide platform, a novel drug design approach intended to neutralize viruses by binding to and disabling them before they infect host cells. Its lead drug candidates are being developed for COVID-19, respiratory syncytial virus (RSV), and influenza, targeting hospital-treated and high-risk patient populations. NanoViricides was founded in 2005 and has evolved from a platform research company into one conducting advanced preclinical and early clinical development, supported by in-house manufacturing capabilities.
Business Operations
NanoViricides’ operations are organized around a single reportable business focused on antiviral drug research and development, with activities spanning drug design, preclinical testing, process development, and limited clinical-stage preparation. The company’s lead development candidate, NV-387, is a broad-spectrum antiviral designed to act against multiple respiratory viruses and is the primary driver of research spending and strategic focus.
The company conducts its research and manufacturing activities primarily through its wholly owned subsidiary NanoViricides, Inc. (Connecticut), which operates a cGMP-capable manufacturing and laboratory facility. NanoViricides also maintains a long-standing licensing relationship with TheraCour Pharma, Inc., a related-party entity that licenses key intellectual property underlying the nanoviricide technology. As of the most recent public disclosures, NanoViricides has no commercial partnerships generating revenue and relies on equity financing to fund operations.
Strategic Position & Investments
NanoViricides’ strategy centers on advancing NV-387 through clinical development while leveraging its platform to generate additional antiviral candidates targeting other viral families. The company emphasizes broad-spectrum applicability, aiming to reduce dependency on virus-specific drug development and address pandemic preparedness and emerging viral threats.
Investment priorities include continued enhancement of in-house manufacturing capabilities, preclinical toxicology studies, and regulatory preparation for human trials. The company has not completed any major third-party acquisitions but has invested significantly in proprietary infrastructure and intellectual property licensed from TheraCour Pharma, Inc. Emerging focus areas include pan-coronavirus and pan-influenza antiviral applications, though timelines and outcomes remain dependent on regulatory and clinical progress.
Geographic Footprint
NanoViricides is headquartered in Shelton, Connecticut, which also serves as the company’s primary research, development, and manufacturing location. The company’s operational footprint is concentrated in the United States, with no disclosed commercial operations or clinical trial sites outside the country as of the latest filings.
While NanoViricides does not currently maintain international subsidiaries or revenue-generating operations abroad, its drug development programs are designed for global therapeutic markets, particularly in regions affected by respiratory viral outbreaks. Any future international presence is expected to be tied to clinical trials, regulatory approvals, or commercialization partnerships.
Leadership & Governance
NanoViricides was founded by Anil R. Diwan, who continues to play a central role in defining the company’s scientific and strategic direction. The leadership team combines expertise in polymer chemistry, pharmaceutical development, and corporate finance, with governance overseen by a board that includes both executive and independent directors.
Key executives emphasize a long-term, science-driven development philosophy focused on platform validation and controlled capital deployment. Leadership continuity has been a defining characteristic of the company, though it also concentrates key decision-making authority among a small executive group.
- Anil R. Diwan – President, Executive Chairman, and Chief Executive Officer
- Leo Ehrlich – Chief Financial Officer
- Anil R. Diwan – Founder